# The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

> **NCT01847313** · PHASE3 · COMPLETED · sponsor: **Karl Neff** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT01847313
- **Lead sponsor:** Karl Neff
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01847313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01847313, "The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01847313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*